Bright Minds Biosciences (Bright Minds Biosciences) Debt-to-Asset : 0.01 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Bright Minds Biosciences Debt-to-Asset?

Bright Minds Biosciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.03 Mil. Bright Minds Biosciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.00 Mil. Bright Minds Biosciences's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was $4.83 Mil. Bright Minds Biosciences's debt to asset for the quarter that ended in Mar. 2024 was 0.01.

Bright Minds Biosciences Debt-to-Asset Historical Data

The historical data trend for Bright Minds Biosciences's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bright Minds Biosciences Debt-to-Asset Chart

Bright Minds Biosciences Annual Data

Trend

Sep20

Sep21

Sep22

Sep23

Debt-to-Asset

0.01

Bright Minds Biosciences Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Asset	Get a 7-Day Free Trial													0.01	0.01	0.01	0.01	0.01

Competitive Comparison of Bright Minds Biosciences's Debt-to-Asset

For the Biotechnology subindustry, Bright Minds Biosciences's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bright Minds Biosciences's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bright Minds Biosciences's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Bright Minds Biosciences's Debt-to-Asset falls into.

Bright Minds Biosciences Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Bright Minds Biosciences's Debt-to-Asset for the fiscal year that ended in Sep. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.055	+	0)	/	5.084
	=	0.01

Bright Minds Biosciences's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.026	+	0)	/	4.825
	=	0.01

Bright Minds Biosciences (NAS:DRUG) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Bright Minds Biosciences Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Bright Minds Biosciences's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Bright Minds Biosciences (Bright Minds Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bright Minds Biosciences Inc (NAS:DRUG) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

DRUG:Canada

Address

19 Vestry Street, New York, NY, USA, 10013

Website

https://www.brightmindsbio.com

Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.